Clinical trial NCT05335980: Nu-V3 Non-Invasive Nerve Stimulation Device Trial for Chronic Pain, Anxiety, Depression, Sleeplessness
Official title: A Phase II Prospective, Single-Arm, Open-Label, Multi-Center Study Using the Nu-V3 Cranial Nerve Stimulation Treatment Device in Patients With Chronic Pain, Anxiety, Depression, and/or Sleeplessness
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Chronic Pain
Anxiety
Depression
Sleeplessness
Keywords: Device
TENS
Neuromodulation
PTSD
Neuropathy
Inflammatory
Arthritis
Chronic Pain
Fibromyalgia
Osteoarthritis
TMJ
Insomnia
Lead sponsor: Nu-Life Solutions
Sponsor class: INDUSTRY
First posted: 2022-04-20
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A Phase II Prospective, Single-Arm, Open-Label, Multi-Center Study Using the Nu-V3 Cranial Nerve Stimulation Treatment Device in Patients with Chronic Pain, Anxiety, Depression, and/or Sleeplessness
Primary purpose: TREATMENT

Brief summary: The Nu-V3 Clinical Study is a prospective, single-arm, open-label, multi-center study using the Nu-V3 cranial nerve stimulation treatment device in patients with chronic pain, anxiety, depression, and/or sleeplessness.

For this Phase II study, a total of 100-200 patients at multiple centers will be registered for study participation. Study participants are those who have signed the informed consent form, met the inclusion and exclusion criteria, and are enrolled in the study at one of multiple sites. Enrolled participants are stratified based on their chronic pain, anxiety, depression, and/or sleeplessness symptom presentation at baseline and treated with the Nu-V3 device for 24 weeks. Interim analysis of reported data will be based on baseline stratifications and conducted at 6, 12, 18, and 24 weeks during this time. The participant will be evaluated after the initial 12-week treatment period to assess for further therapeutic need. Upon having three consecutive weeks of mean symptom reduction of ≥70% via patient reported numerical scales, the participant will continue as described in the study assessments table, but without device therapy. Then if the participant's primary symptom score increases at any time by ≥20%, they may again continue device therapy until week 24.

Detailed description: Subjects enrolled onto the Nu-V3 Clinical Trial will undergo the following regimen:

* At the baseline visit, patients will be asked to complete study questionnaires regarding all of the following symptoms: chronic pain, anxiety, depression, and/or sleeplessness, as well as their quality of life, active medications, medical history, and demographic information. The subject's primary symptom of concern will also be notated at baseline, for later assessment of continuation after week 12.
* At each subsequent visit, patients will be asked to complete study questionnaires regarding all the following symptoms: chronic pain, anxiety, depression, and/or sleeplessness, as well as their activity level and quality of life.
* The sessions will begin with the Nu-V3 device being clipped on the ear and three small pads (non-invasive) adhered to the surface of the ear. Each Nu-V3 device lasts for up to 14 days with a change in the pads approximately 7 days into the treatment.
* Each session takes approximately 15-20 minutes. The placement of the device takes approximately 5 minutes and the remaining time is spent verifying ePRO form completion, and evaluating the patient for all device effects.
* The Nu-V3 device is mobile and is worn externally on the left ear 24 hours a day during treatment, fitting comfortably behind the ear. An electrical signal is sent to the external ear through coated wire leads attached to the device and adhesive pads which attach to three sites on the ear.
* Participants should be able to perform their typical day-to-day activities while wearing the device. They may shower while wearing the Nu-V3 device, provided that they do not get the device wet and use the small disposable ear covers that are provided for them.
* In the event the Nu-V3 gel pads are inadvertently removed or the device comes off, the participant will contact the site coordinator. The participant is encouraged to adjust the device placement as needed for comfort.
* Patients should not change their existing forms of treatment or medications without discussion with the study investigator.

Eligibility criteria: Inclusion Criteria:

* Participant is at least 18 years of age
* Participant presents with one or more of the following symptoms: pain, depression, anxiety, and/or sleeplessness
* Participant is capable of understanding the use and maintenance of the device
* Participant is capable and agreeing to participate in the ongoing assessment
* Participant has signed the Informed Consent Form
* Participant can commit to follow all protocol study timepoints

Exclusion Criteria:

* Participants with a Pacemaker
* Participants with irregular heart rate or a heart rate lower than 60 beats per minute (bradycardia)
* Have had a transplant within the last 2 years
* Have had a heart attack or cardiac bypass surgery within the last 12 months
* History of substance abuse, including prescription drugs, within the last 12 months
* Patients with complaints of dizziness or lightheadedness within the last 3 months
* Women who are pregnant
* Participants with Diabetic Retinopathy
* Current Ear infection
* SBP \< 100 and/or DBP \< 60
* History of uncontrolled bipolar disorder within the last 12 months
* History of uncontrolled seizures within the last 12 months
* History of Aneurysms
* History of syncope within the last 12 months
* Participants that have had a TIA or stroke within the last 12 months
* Participants with health problems deemed at risk for the study by the Principal Investigator
* Participants with any changes to Pain/Anxiety/Depression/Sleeplessness medications within last 60 days (participants that do not meet this medication- change washout period may be delayed until 60-day period is met)
* Participants that are currently under adjudication process for disability support, VA or other

Primary outcomes:
measure: Effectiveness and overall change in reported primary symptom of concern: Chronic Pain
timeFrame: 12 and 24 weeks
measure: Effectiveness and overall change in reported primary symptom of concern: Anxiety
timeFrame: 12 and 24 weeks
measure: Effectiveness and overall change in reported primary symptom of concern: Depression
timeFrame: 12 and 24 weeks
measure: Effectiveness and overall change in reported primary symptom of concern: Sleeplessness
timeFrame: 12 and 24 weeks
Secondary outcomes:
measure: Effectiveness: Symptom Frequency
timeFrame: 12 and 24 weeks
measure: Effectiveness: Symptom Severity
timeFrame: 12 and 24 weeks
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Arizona Endocrinology
state: Arizona
Study officials:
affiliation: Nu-Life Solutions
name: Bradley Doebbeling, MD
role: STUDY_CHAIR
affiliation: Nu-Life Solutions
name: Kamran Chaudhary, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Nu-Life Solutions
name: Eric T Siebeneck, MS
role: STUDY_DIRECTOR
References: